Get started
Author

Franck Brichory

Global Profiling of the Cell Surface Proteome of Cancer Cells Uncovers an Abundance of Proteins with Chaperone Function
2003 · Bong Kyung Shin, Hong Wang, et al. · Journal of Biological Chemistry · 520
PDF
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer
2001 · Franck M. Brichory, David E. Misek, et al. · Proceedings of the National Academy of Sciences · 355
Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer.
2001 · F Brichory, D Beer, et al. · PubMed · 203
A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis
2002 · François Le Naour, Franck Brichory, et al. · Molecular & Cellular Proteomics · 156
Protein based microarrays: A tool for probing the proteome of cancer cells and tissues
2001 · Juan Madoz-Gúrpide, Hong Wang, et al. · PROTEOMICS · 122
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
2021 · James M. Cleary, Srivatsan Raghavan, et al. · Cancer Discovery · 95
A database of protein expression in lung cancer
2001 · Jane M. C. Oh, Franck Brichory, et al. · PROTEOMICS · 77
Galectin-8: a complex sub-family of galectins (Review)
2001 · Nathalie Bidon, Franck Brichory, et al. · International Journal of Molecular Medicine · 68
Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice
2003 · Chad Creighton, Rork Kuick, et al. · Genome biology · 59
PDF
A Proteomic Approach to the Identification of Lung Cancer Markers
2001 · Samir Hanash, Franck Brichory, et al. · Disease Markers · 55
PDF
Preclinical Characterization of DPI-4452: A68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX
2024 · Frédéric Massière, Norbert Wiedemann, et al. · Journal of Nuclear Medicine · 54
PDF
Two messenger RNAs and five isoforms for Po66-CBP, a galectin-8 homolog in a human lung carcinoma cell line
2001 · Nathalie Bidon, Franck Brichory, et al. · Gene · 47
Identification of Tumor-Associated Antigens Using Proteomics
2002 · François Le Naour, Franck Brichory, et al. · Technology in Cancer Research & Treatment · 37
PDF
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
2021 · Carlos Gomez‐Roca, Caroline Even, et al. · Clinical and Translational Science · 23
Scaled-Down Purification Protocol To Access Proteomic Analysis of 20S Proteasome from Human Tissue Samples: Comparison of Normal and Tumor Colorectal Cells
2008 · Manuelle Ducoux-Petit, Sandrine Uttenweiler-Joseph, et al. · Journal of Proteome Research · 19
Immunohistochemical Expression of the Intracellular Component of Galectin-8 in Squamous Cell Metaplasiaof the Bronchial Epitheliumin Neoplastic and Benign Processes
2001 · Sylvie Caulet-Maugendre, Sophie Birolleau, et al. · Pathology - Research and Practice · 13
Abstract 5001: Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck
2019 · Carlos Gomez-Roca, Caroline Even, et al. · Cancer Research · 6
Tri-n-octyl[32P]phosphine oxide. synthesis and biodistributionvia the hepatic artery of rats
1999 · Anne-Dominique Fortineau, Franck Brichory, et al. · Journal of Labelled Compounds and Radiopharmaceuticals · 5
Sodium butyrate induces growth inhibition and modulates galectin-8 expression in human lung carcinoma cells.
2001 · N Bidon, F Brichory, et al. · PubMed · 3
Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study
2025 · Glenwood Goss, Tudor Ciuleanu, et al. · Therapeutic Advances in Medical Oncology · 2
Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses
2023 · Quincy Chu, Tudor Ciuleanu, et al. · Cancer Research · 1
Abstract 3443: The IAP antagonist xevinapant, in combination with high-dose cisplatin chemoradiotherapy, induces NF-kB and apoptotic pathway biomarkers in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
2022 · Luke Piggott, Bruno Gavillet, et al. · Cancer Research · 1
Abstract 5001: Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck
2019 · Carlos Gomez-Roca, Caroline Even, et al. · Clinical Research (Excluding Clinical Trials) · 1
Abstract 2088: The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression
2017 · Franck Brichory, Anna Pokorska-Bocci, et al. · Cancer Research · 1
Abstract 4784: FGFR-selective inhibitor Debio 1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models
2016 · Brichory Franck, Anna Pokorska-Bocci, et al. · Cancer Research · 1
Works count: 31
Citation count: 1,924
H-index: 15
I10-index: 16
Year
Topic
Type